Catalent vs Piramal Pharma Solutions: CDMO Comparison

How does Catalent compare to Piramal Pharma Solutions for ADC manufacturing?

As of Oct 2026, Catalent: 24 FDA inspections (including 7 NAI, 15 VAI and 2 OAI), 1 FDA warning letter, 39 EMA/MHRA GMP certificates. Signal Score 76.1. Piramal Pharma Solutions: 7 FDA inspections (including 3 NAI, 4 VAI and 0 OAI), 15 EMA/MHRA GMP certificates. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Catalent and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Tampa, FL
Signal Score
76/100
Quality (FDA + GMP)
77/100
FDA inspections
24
— NAI / VAI / OAI
7 / 15 / 2
FDA warning letters
1
EMA GMP certificates (active)
21
MHRA GMP certificates (compliant)
18
Clinical programs (matched)
0
Capacity
—
Modalities
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score
87/100
Quality (FDA + GMP)
96/100
FDA inspections
7
— NAI / VAI / OAI
3 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
1
MHRA GMP certificates (compliant)
14
Clinical programs (matched)
0
Capacity
—
Modalities
Biologics, ADC, Small Molecule API, High-Potency APIs, Oral Solid Dose

Key differences

  • Catalent has more FDA inspections on record (24 vs 7) — a deeper regulatory paper trail.
  • Piramal Pharma Solutions carries a cleaner inspection mix — no OAI classifications versus 2 for Catalent.
  • Catalent has 1 FDA warning letter on record; Piramal Pharma Solutions has none.
  • Catalent has materially broader EMA GMP coverage (21 active certificates vs 1) — stronger EU footprint.
  • Composite Signal Score: Piramal Pharma Solutions 87/100 vs Catalent 76/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both Catalent and Piramal Pharma Solutions qualify as ADC manufacturers; Piramal Pharma Solutions carries the higher composite Signal Score for ADC programs in this comparison.

What to evaluate for ADC programs

Both Catalent and Piramal Pharma Solutions qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

HPAPI containment

Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.

Linker-payload chemistry on file

Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.

Commercial bioconjugation track record

Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.

Integrated DS + DP

Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.

See all ADC CDMOs ranked by Signal Score →

Frequently asked: Catalent vs Piramal Pharma Solutions

How does Catalent compare to Piramal Pharma Solutions for ADC manufacturing?

On CDMO Signal's composite Signal Score, Catalent is 76/100 and Piramal Pharma Solutions is 87/100; Catalent has 24 FDA inspections on record vs 7 for Piramal Pharma Solutions; European coverage is 39 active EMA+MHRA certificates for Catalent vs 15 for Piramal Pharma Solutions. Both are tracked in the CDMO Signal directory as ADC CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Catalent or Piramal Pharma Solutions?

Catalent has 24 FDA inspections on record (NAI 7 / VAI 15 / OAI 2) and 1 warning letter. Piramal Pharma Solutions has 7 FDA inspections on record (NAI 3 / VAI 4 / OAI 0) and 0 warning letters.

How do Catalent and Piramal Pharma Solutions compare on European GMP coverage?

Catalent holds 21 active EMA GMP certificates and 18 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 14 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for ADC manufacturing — Catalent or Piramal Pharma Solutions?

Both Catalent and Piramal Pharma Solutions are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Catalent carries a Signal Score of 76/100 and Piramal Pharma Solutions carries 87/100 — a meaningful lead for Piramal Pharma Solutions. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Catalent and Piramal Pharma Solutions for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.